News

Episode 6 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and David G Standaert, MD, PhD, of University of Alabama at Birmingham. [WATCH TIME: 4 minutes]

Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.

The AASM board of directors member and professor of medicine at UCLA discussed some strengths of CBT.

Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.

Neurocrine Biosciences and Voyager Therapeutics have terminated the Parkinson disease portion of their partnership, ending development for VY-AADC, also known as NBIb-1817.

RACE, G-FAST, and CG-FAST were among the best performing prehospital stroke scales out of 8 scales tested and approached the performance of the clinician-assessed NIHSS.

The director of the Massachusetts General Hospital ALS Care Center spoke on the importance of data-based registries and how they can grow ALS research.

Treatment with low-dose protocol of rituximab is sufficient to maintain suppression of inflammatory disease activity in most patients with relapsing-remitting multiple sclerosis.

The results suggest that BACE-1 inhibitors, while a promising option to slow progression of Alzheimer disease, require further study with careful safety monitoring.

After Theranica’s remote electrical neuromodulation was approved for those aged 12 years and older with migraine, study investigator Jennifer McVige, MD, MA, shared her insight.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine explained the various factors that make Parkinson so difficult to manage.

Data suggest that treatment-emergent adverse events with adjunctive brivaracetam increased in incidence by number of lifetime AEDs.

The basis of the approval for peginterferon beta-1a was from a phase 1 crossover study that showed the drug’s bioequivalence to subcutaneous injection.

The neurologist from Cleveland Clinic discussed perampanel’s unique mechanism of action.

Here's what is coming soon to NeurologyLive.

The director of the Dartmouth Epilepsy Program discussed a few of the notable highlights and themes from the recently completed American Epilepsy Society Annual Meeting.

The researchers noted that the recovery model can use all available serially assessed data in a flexible way, creating a prediction at any desired moment poststroke, stand-alone, or linked with an electronic health record system.

Jude Savarraj, PhD, discusses the accurate performance of his team’s machine learning models in predicting subarachnoid hemorrhage outcomes.

The director of the Massachusetts General Hospital ALS Care Center discussed the origins of ‘The Data is Here’ campaign and the reason to launch it now.

Clinically relevant scores of 32 and 44 on the Fugl-Meyer Motor Score were documented in 2 patients who received NSI-566.

Neurology News Network for the week ending January 30, 2021.

The study also found that patients with PD that used telehealth for mental health services were less likely to prefer telehealth over in-office visits.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

The investigational agent developed by Biogen and Eisai is now expected to receive regulatory review by June 7, 2021.

The observed increase in QOLIE-31 scores for patients with refractory disease was driven by increases on the energy-fatigue domain.

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation between an expert neurologist, psychologist, patient, and care partner on various facets of multiple sclerosis.